Prolactin Protects the Structural Integrity of Human Fetal Membranes by Downregulating Inflammation-induced Secretion of Matrix Metalloproteinases

Immunol Invest. 2022 Jul;51(5):1313-1329. doi: 10.1080/08820139.2021.1936012. Epub 2021 Jun 16.

Abstract

Prolactin (PRL) is a pleiotropic hormone with a key role in pregnancy. In fetal membranes, PRL can regulate the secretion of pro-inflammatory factors, which induces the activation of matrix metalloproteinases (MMPs). The increase and activation of MMPs deregulate the turnover of the extracellular matrix in the fetal membranes, altering its structure and function, causing premature rupture of the membranes and preterm labor. In this work, we evaluate the effect of PRL upon the secretion of MMP-1, MMP-2, MMP-9, MMP-13, and the tissue inhibitors of metalloproteinases (TIMPs) in human fetal membranes after lipopolysaccharide (LPS) challenge. Nine fetal membranes from healthy non-laboring cesarean deliveries at term were cultured in a 2-independent chamber system and pre-treated with 250, 500, 1000 or 4000 ng/ml of PRL for 24 h, then choriodecidual region was stimulated with 500 ng/ml of LPS plus fresh PRL for 24 h. The MMPs and TIMPs secretion were quantified by ELISA, additionally MMP-2 and MMP-9 gelatinolytic activity was measured by zymography. LPS induced the MMP-9 and MMP-1 secretion, but no MMP-2 or MMP-13 in comparison with basal levels. PRL co-treatment decreased the MMP-2, MMP-9 and MMP-1 secretion induced by LPS. The active forms were present in the tissue extract, showing a response consistent with the secretion profile. TIMP-1 and TIMP-2 secretion was decreased after LPS treatment and the PRL co-treatment reverts this effect. The present results support that PRL may favor the balance between these factors involved in the structural maintenance of fetal membranes in an inflammatory event.

Keywords: Amnion; TIMP-1; TIMP-2; choriodecidua; extracellular matrix; inflammation; matrix metalloproteinase.

MeSH terms

  • Anti-Inflammatory Agents* / pharmacology
  • Down-Regulation
  • Extraembryonic Membranes* / drug effects
  • Extraembryonic Membranes* / metabolism
  • Female
  • Humans
  • Inflammation* / drug therapy
  • Inflammation* / etiology
  • Inflammation* / metabolism
  • Inflammation* / therapy
  • Lipopolysaccharides / adverse effects
  • Matrix Metalloproteinase 1 / metabolism
  • Matrix Metalloproteinase 13 / metabolism
  • Matrix Metalloproteinase 9* / metabolism
  • Matrix Metalloproteinases, Secreted* / metabolism
  • Pregnancy
  • Prolactin* / pharmacology
  • Tissue Culture Techniques
  • Tissue Inhibitor of Metalloproteinases / metabolism

Substances

  • Anti-Inflammatory Agents
  • Lipopolysaccharides
  • Tissue Inhibitor of Metalloproteinases
  • Prolactin
  • Matrix Metalloproteinase 13
  • Matrix Metalloproteinases, Secreted
  • Matrix Metalloproteinase 9
  • Matrix Metalloproteinase 1